Inflammatory pathways in heart failure with preserved left ventricular ejection fraction: implications for future interventions
Open accessThe DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.
Abstract
Many patients with symptoms and signs of heart failure have a left ventricular ejection fraction ≥50%, termed heart failure with preserved ejection fraction (HFpEF). HFpEF is a heterogeneous syndrome mainly affecting older people who have many other cardiac and non-cardiac conditions that often cast doubt on the origin of symptoms, such as breathlessness, or signs, such as peripheral oedema, rendering them neither sensitive nor specific to the diagnosis of HFpEF. Currently, management of HFpEF is mainly directed at controlling symptoms and treating comorbid conditions such as hypertension, atrial fibrillation, anaemia, and coronary artery disease. HFpEF is also characterized by a persistent increase in inflammatory biomarkers. Inflammation may be a key driver of the development and progression of HFpEF and many of its associated comorbidities. Detailed characterization of specific inflammatory pathways may provide insights into the pathophysiology of HFpEF and guide its future management. There is growing interest in novel therapies specifically designed to target deregulated inflammation in many therapeutic areas, including cardiovascular disease. However, large-scale clinical trials investigating the effectiveness of anti-inflammatory treatments in HFpEF are still lacking. In this manuscript, we review the role of inflammation in HFpEF and the possible implications for future trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationAntiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Rosuvastatin to Prevent Vascular Events in Men and Women with Elevated C-Reactive Protein
Ridker, P. M., Danielson, E., Fonseca, F. A. H., Genest, J., Gotto, A. M., Kastelein, J. J. P., Koenig, W., Libby, P., Lorenzatti, A. J., MacFadyen, J. G., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa0807646 · Cited by 6,674 · cited 1×
“133 Administration of rosuvastatin is associated with a reduction in hsCRP. 134 Nevertheless, in patients with HF, the effect of statins on disease progression and death remains uncertain.”
BackgroundInflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men
Ridker, P. M., Cushman, M., Stampfer, M. J., Tracy, R. P., & Hennekens, C. H. (1997) · New England Journal of Medicine · doi:10.1056/nejm199704033361401 · Cited by 5,504
Cardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206 · cited 1×
“130,131,157 In the EMPEROR-Preserved trial, nearly 6000 patients with chronic HF and a LVEF > 40% were randomized to empagliflozin or placebo.”
BackgroundSelf-citationEmpagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874 · cited 8×
“1 Recently, a RCT on a factor Xa antagonist demonstrated a substantial reduction in mortality for patients with HFpEF and coronary artery disease (CAD), 9 while two others found that sodium-glucose cotransporter-2 inhibitors (SGLT2i) reduce hospitalizations for worsening HF. 10,11 These trials showing that the natural…”
BackgroundInfluentialSelf-citationA Novel Paradigm for Heart Failure With Preserved Ejection Fraction
Paulus, W. J., & Tschöpe, C. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.02.092 · Cited by 3,564 · cited 4×
“16 Oxidative stress might also be implicated in the development of metabolic heart disease, indicating bidirectional links between inflammation and cardiac dysfunction.”
BackgroundInfluentialEfficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159
Endothelial Function and Dysfunction: Testing and Clinical Relevance
Deanfield, J. E., Halcox, J. P., & Rabelink, T. J. (2007) · Circulation · doi:10.1161/circulationaha.106.652859 · Cited by 2,710
Rivaroxaban with or without aspirin in stable cardiovascular disease
Eikelboom, J. W., Connolly, S. J., Bosch, J., Dagenais, G. R., Hart, R. G., Shestakovska, O., Diaz, R., Alings, M., Lonn, E. M., Anand, S. S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1709118 · Cited by 2,438 · cited 1×
“172 The overall result was driven by a large benefit in a subgroup of 4250 patients with HFpEF and mild symptoms; 9 patients with severe symptoms had been excluded.”
BackgroundSelf-citationColchicine in Patients with Chronic Coronary Disease
Nidorf, S. M., Fiolet, A. T. L., Mosterd, A., Eikelboom, J. W., Schut, A., Opstal, T. S. J., The, S. H. K., Xu, X.-F., Ireland, M. A., Lenderink, T., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2021372 · Cited by 2,299
Sotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Chung, E. S., Packer, M., Lo, K. H., Fasanmade, A. A., & Willerson, J. T. (2003) · Circulation · doi:10.1161/01.cir.0000077913.60364.d2 · Cited by 1,644
Rosuvastatin in older patients with systolic heart failure
Kjekshus, J., Apetrei, E., Barrios, V., Böhm, M., Cleland, J. G. F., Cornel, J. H., Dunselman, P., Fonseca, C., Goudev, A., Grande, P., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa0706201 · Cited by 1,487
Self-citationRole of nitric oxide in inflammatory diseases
Sharma, J. N., Al-Omran, A., & Parvathy, S. S. (2007) · Inflammopharmacology · doi:10.1007/s10787-007-0013-x · Cited by 1,403
Vericiguat in patients with heart failure and reduced ejection fraction
Armstrong, P. W., Pieske, B., Anstrom, K. J., Ezekowitz, J., Hernandez, A. F., Butler, J., Lam, C. S. P., Ponikowski, P., Voors, A. A., Jia, G., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa1915928 · Cited by 1,358 · cited 1×
“HFrEF, the VICTORIA trial suggested a reduction in morbidity and mortality, except in those with a very high NT-proBNP (>5314 ng/L) who appeared to be harmed.(123) However, for patients with HFpEF (SOCRATES-PRESERVED, n = 477 and VITALITY-HFpEF, n = 789), vericiguat failed to reduce plasma NT-proBNP concentrations, le…”
BackgroundGISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61239-8 · Cited by 1,350
Low-Dose Methotrexate for the Prevention of Atherosclerotic Events
Ridker, P. M., Everett, B. M., Pradhan, A., MacFadyen, J. G., Solomon, D. H., Zaharris, E., Mam, V., Hasan, A., Rosenberg, Y., Iturriaga, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1809798 · Cited by 1,317 · cited 1×
“92 Most of these trials excluded patients with moderate or severe HF, did not always include HF-related endpoints and often did not provide data on LVEF, 93,95–100, 102, 104, 105 limiting extrapolation of their results”
BackgroundMann, D. L., McMurray, J. J. V., Packer, M., Swedberg, K., Borer, J. S., Colucci, W. S., Djian, J., Drexler, H., Feldman, A., Kober, L., et al. (2004) · Circulation · doi:10.1161/01.cir.0000124490.27666.b2 · Cited by 1,240
Frangogiannis, N. G. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa324 · Cited by 1,229
Obokata, M., Reddy, Y. N. V., Pislaru, S. V., Melenovsky, V., & Borlaug, B. A. (2017) · Circulation · doi:10.1161/circulationaha.116.026807 · Cited by 1,179
GISSI-HF investigators (2008) · The Lancet · doi:10.1016/s0140-6736(08)61240-4 · Cited by 1,106
Interplay between inflammation and thrombosis in cardiovascular pathology
Stark, K., & Massberg, S. (2021) · Nature Reviews Cardiology · doi:10.1038/s41569-021-00552-1 · Cited by 1,033 · cited 8×
“…of inflammatory pathways induces microvascular dysfunction and increases the risk of thrombotic events contributing to the progression of HF. 171 The generation of thrombin can amplify the effects of other stimuli on inflammatory pathways, which might be ameliorated by reducing its…”
BackgroundInfluentialNitric oxide signalling in cardiovascular health and disease
Farah, C., Michel, L. Y. M., & Balligand, J.-L. (2018) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2017.224 · Cited by 779
Bajpai, G., Bredemeyer, A., Li, W., Zaitsev, K., Koenig, A. L., Lokshina, I., Mohan, J., Ivey, B., Hsiao, H.-M., Weinheimer, C., et al. (2019) · Circulation Research · doi:10.1161/circresaha.118.314028 · Cited by 751 · cited 1×
“Mice that developed chronic HF following coronary artery ligation had an increase in CCR2 + /CCR2 – ratio 188 ; findings subsequently confirmed in human hearts.”
BackgroundThe human heart contains distinct macrophage subsets with divergent origins and functions
Bajpai, G., Schneider, C., Wong, N., Bredemeyer, A., Hulsmans, M., Nahrendorf, M., Epelman, S., Kreisel, D., Liu, Y., Itoh, A., et al. (2018) · Nature Medicine · doi:10.1038/s41591-018-0059-x · Cited by 712 · cited 1×
“189 An intense proliferation of CCR2 + macrophages has also been described in murine models of pressure overload obtained by aortic constriction.”
BackgroundEchocardiographic epicardial fat: a review of research and clinical applications
Iacobellis, G., & Willens, H. J. (2009) · Journal of the American Society of Echocardiography · doi:10.1016/j.echo.2009.10.013 · Cited by 700
Hambrecht, R. (2000) · JAMA · doi:10.1001/jama.283.23.3095 · Cited by 689
Evaluation and management of heart failure with preserved ejection fraction
Borlaug, B. A. (2020) · Nature Reviews Cardiology · doi:10.1038/s41569-020-0363-2 · Cited by 675
Anti-Inflammatory Therapy With Canakinumab for the Prevention of Hospitalization for Heart Failure
Everett, B. M., Cornel, J. H., Lainscak, M., Anker, S. D., Abbate, A., Thuren, T., Libby, P., Glynn, R. J., & Ridker, P. M. (2019) · Circulation · doi:10.1161/circulationaha.118.038010 · Cited by 658
Packer, M. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2018.03.509 · Cited by 656 · cited 1×
“In patients with HFpEF, EAT accumulation is often marked, and it promotes haemodynamic derangements, 31–33 altered adipogenesis by secretion of pro-inflammatory and pro-atherogenic adipokines, 34 and an adverse prognosis.”
BackgroundAnti-inflammatory effects of exercise: role in diabetes and cardiovascular disease
Pedersen, B. K. (2017) · European Journal of Clinical Investigation · doi:10.1111/eci.12781 · Cited by 617
Darapladib for Preventing Ischemic Events in Stable Coronary Heart Disease
The STABILITY Investigators (2014) · New England Journal of Medicine · doi:10.1056/nejmoa1315878 · Cited by 579
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Rådholm, K., Figtree, G., Perkovic, V., Solomon, S. D., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Barrett, T. D., Shaw, W., Desai, M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034222 · Cited by 488
Exercise Intolerance in Patients With Heart Failure
Del Buono, M. G., Arena, R., Borlaug, B. A., Carbone, S., Canada, J. M., Kirkman, D. L., Garten, R., Rodriguez-Miguelez, P., Guazzi, M., Lavie, C. J., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.01.072 · Cited by 477 · cited 1×
“4 Exercise training Impaired exercise capacity is a hallmark of HFpEF,(194) which is likely to be multifactorial, including cardiac dysfunction, skeletal muscle deconditioning, obesity, co-existent lung or joint disease, and psychological factors.(195) In patients with HFpEF, endurance exercise training was associated…”
BackgroundHeerspink, H. J. L., Perco, P., Mulder, S., Leierer, J., Hansen, M. K., Heinzel, A., & Mayer, G. (2019) · Diabetologia · doi:10.1007/s00125-019-4859-4 · Cited by 457
O’Donoghue, M. L., Braunwald, E., White, H. D., Steen, D. P., Lukas, M. A., Tarka, E., Steg, P. G., Hochman, J. S., Bode, C., Maggioni, A. P., et al. (2014) · JAMA · doi:10.1001/jama.2014.11061 · Cited by 456
Periodontitis is associated with hypertension: a systematic review and meta-analysis
Muñoz Aguilera, E., Suvan, J., Buti, J., Czesnikiewicz-Guzik, M., Barbosa Ribeiro, A., Orlandi, M., Guzik, T. J., Hingorani, A. D., Nart, J., & D’Aiuto, F. (2020) · Cardiovascular Research · doi:10.1093/cvr/cvz201 · Cited by 394
Self-citationHambrecht, R., Fiehn, E., Yu, J., Niebauer, J., Weigl, C., Hilbrich, L., Adams, V., Riede, U., & Schuler, G. (1997) · Journal of the American College of Cardiology · doi:10.1016/s0735-1097(97)00015-6 · Cited by 386
Kitzman, D. W., Brubaker, P. H., Herrington, D. M., Morgan, T. M., Stewart, K. P., Hundley, W. G., Abdelhamed, A., & Haykowsky, M. J. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2013.04.033 · Cited by 369 · cited 1×
“196,197 Physical training reduces systemic vascular resistance 198 and increases skeletal muscle perfusion, peripheral oxygen utilization, and mitochondrial function.”
BackgroundPieske, B., Maggioni, A. P., Lam, C. S. P., Pieske-Kraigher, E., Filippatos, G., Butler, J., Ponikowski, P., Shah, S. J., Solomon, S. D., Scalise, A.-V., et al. (2017) · European Heart Journal · doi:10.1093/eurheartj/ehw593 · Cited by 366 · cited 1×
“121,124”
Rivaroxaban in Patients with Heart Failure, Sinus Rhythm, and Coronary Disease
Zannad, F., Anker, S. D., Byra, W. M., Cleland, J. G. F., Fu, M., Gheorghiade, M., Lam, C. S. P., Mehra, M. R., Neaton, J. D., Nessel, C. C., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1808848 · Cited by 345 · cited 1×
“173 Overall, these data suggest that the efficacy of this intervention, as for many others, depends on the patient profile.”
BackgroundSelf-citationPatel, B., Bansal, S. S., Ismahil, M. A., Hamid, T., Rokosh, G., Mack, M., & Prabhu, S. D. (2018) · JACC: Basic to Translational Science · doi:10.1016/j.jacbts.2017.12.006 · Cited by 297 · cited 1×
“190 CCR2 modulation could represent a potential target to reduce inflammation and block the development of HFpEF: in murine models of angiotensin-II-induced HFpEF, inhibition of CCR2 + macrophages improved diastolic function, 191 while in humans, the anti-CCR2 humanized monoclonal antibody MLN1202…”
BackgroundKoepp, K. E., Obokata, M., Reddy, Y. N. V., Olson, T. P., & Borlaug, B. A. (2020) · JACC Heart Failure · doi:10.1016/j.jchf.2020.04.016 · Cited by 269
Recio-Mayoral, A., Mason, J. C., Kaski, J. C., Rubens, M. B., Harari, O. A., & Camici, P. G. (2009) · European Heart Journal · doi:10.1093/eurheartj/ehp205 · Cited by 235 · cited 1×
“Also, chronic inflammation, even in the absence of epicardial stenoses and traditional coronary risk factors, is associated with CMD.(115) Inflammation has been the therapeutic target for many RCTs that enrolled only patients with HF (Table 2 and Figure 2), but, until now, most of them were focused on the HFrEF phenot…”
BackgroundIsolated Quadriceps Training Increases Maximal Exercise Capacity in Chronic Heart Failure
Esposito, F., Reese, V., Shabetai, R., Wagner, P. D., & Richardson, R. S. (2011) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2011.06.025 · Cited by 175
Preiss, D., Campbell, R. T., Murray, H. M., Ford, I., Packard, C. J., Sattar, N., Rahimi, K., Colhoun, H. M., Waters, D. D., LaRosa, J. C., et al. (2015) · European Heart Journal · doi:10.1093/eurheartj/ehv072 · Cited by 160
Packer, M. (2021) · Cardiovascular Research · doi:10.1093/cvr/cvaa064 · Cited by 86
Launbo, N., Zobel, E. H., von Scholten, B. J., Færch, K., Jørgensen, P. G., & Christensen, R. H. (2021) · Obesity Reviews · doi:10.1111/obr.13136 · Cited by 76
Sharma, S., Sridhar, S., McIntosh, A., Messow, C.-M., Aguilera, E. M., Del Pinto, R., Pietropaoli, D., Gorska, R., Siedlinski, M., Maffia, P., et al. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105511 · Cited by 53 · cited 1×
“49,50”
Self-citation
Cited by
Tirzepatide Reduces LV Mass and Paracardiac Adipose Tissue in Obesity-Related Heart Failure
Kramer, C. M., Borlaug, B. A., Zile, M. R., Ruff, D., DiMaria, J. M., Menon, V., Ou, Y., Zarante, A. M., Hurt, K. C., Murakami, M., et al. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2024.11.001 · Cited by 200
Autoimmune Disorders in Heart Failure With Preserved Ejection Fraction
Tada, A., Doi, S., Harada, T., Ibe, T., Naser, J. A., Amdahl, M., Reddy, Y. N. V., & Borlaug, B. A. (2024) · JACC: Heart Failure · doi:10.1016/j.jchf.2024.04.016 · Cited by 25
Pugliese, N. R., Paneni, F., Tricò, D., Bacca, A. V., De Biase, N., Dalpiaz, H., Mengozzi, A., Virdis, A., Ghiadoni, L., Taddei, S., et al. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02778-6 · Cited by 16
“Moreover, it regulates the inflammatory and atherogenic balance in a paracrine fashion through the production and secretion of adipokines [85, 86].”
Self-citation
Metadata
- Authors
- Pugliese, N. R., Pellicori, P., Filidei, F., De Biase, N., Maffia, P., Guzik, T. J., Masi, S., Taddei, S., & Cleland, J. G. F.
- Venue
- Cardiovascular Research
- Publisher
- Oxford University Press (OUP)
- Published
- 2022-08-25
- Volume
- 118
- Issue
- 18
- Pages
- 3536-3555
- ISSN
- 0008-6363 (ISSN-L)
- 1755-3245
- OpenAlex
- W4293105430
- Cited by
- 144
- References
- 51
- FWCI
- 16.79
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.